经济观察网 据威斯克生物微信公众号消息，近日，由威斯克生物联合四川大学华西医院自主研发的痤 疮治疗性疫苗，正式获得中国国家药品监督管理局（NMPA）新药临床试验申请（IND）批准，成为我 国首款进入临床阶段的痤疮治疗性疫苗。威斯克生物是一家创新型生物医药企业，2021—2025年连续四 年成功入选独角兽企业，在北京、成都和广州设立了研发、生产和销售机构。 ...

大赛虽已收官，但创新创业的故事才刚刚启幕。从7146个项目中脱颖而出的优秀团队，正手握技术的利 刃，怀揣改变世界的热情，成为湾区建设中最具活力的"新星力量"。 为持续讲述这些动人的创新篇章，本系列报道推出专题《湾区创talk·一期一会》。以"一期一会"为主 线，我们将一次次走近大赛获奖项目，记录思想的碰撞、技术的迭代与梦想的生长——创业菁英们用人 工智能重塑生产力，以生物医药守护人类健康，借智能装备升级传统行业，凭文化创意点亮美好生活。 从院士领衔的尖端平台，到青年学子的奇思妙想；从意向融资过亿的"航母项目"，到扎根田野的智 能"农夫"……每一次相遇，都是对创新精神的致敬；每一次"一期一会"，都是湾区未来的注脚。 在刚刚落幕的2025年粤港澳大湾区创业大赛的舞台上，一个来自香港的艾滋病治疗性核酸疫苗项目脱颖 而出。医克生物行政总裁兼联合创始人金侠在进行了12分钟的路演与答疑后，项目不仅斩获大赛生物医 药赛道特等奖，更收获了四家投资机构总额8500万元的意向投资。 其中，意向出资最高的川商基金当场与团队签署投资意向书。两周之后，双方在上海进行了近4小时的 闭门会谈，继续深入了解。这一项目的独创性在哪里？从香港走 ...

Core Insights - The 2025 Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition showcased innovative projects, with a focus on technology and future industries [2] - The competition highlighted the collaboration between Hong Kong and mainland China in fostering biotech innovations, particularly in the context of the ICVAX HIV therapeutic vaccine project [4][8] Company Highlights - The ICVAX project, developed by MedK Bio, is based on patented technology from the University of Hong Kong, enhancing immune response against HIV [4][8] - MedK Bio secured a total of 85 million yuan in investment intentions from four institutions during the competition, with the highest single offer reaching 60 million yuan [7][13] - The project has achieved a 100% follow-up rate in its clinical trials, with safety and immunogenicity data exceeding expectations [4][5] Industry Collaboration - The project exemplifies the synergy between Hong Kong's research capabilities and mainland China's clinical resources, with Shenzhen Third People's Hospital serving as the primary clinical trial site [8][9] - MedK Bio's development path illustrates the integration of resources across the Greater Bay Area, enhancing the region's biotech innovation landscape [14] Future Prospects - MedK Bio plans to advance to Phase II clinical trials for ICVAX and expand its portfolio to include treatments for other infectious diseases and cancers, aiming for commercialization by 2028 [13][14] - The company is also collaborating with the National Manufacturing Innovation Center based in Shenzhen to establish a new laboratory [13]

荷牧生物由国内先进的技术开发团队及实力强大的管理团队共同打造，是国内首家专注于动物新型 mRNA疫苗创新型研发企业。致力于新型动物病毒性传染病mRNA疫苗研发，通过不断的产品创新，提 供更安全更有效的新型疫苗。 同时开展精准的动物传染病体外检测试剂研发，建立全面完善的病原检 测及预防解决方案，为全国乃至世界的畜牧业健康发展提供保障。 | 公布日 | 投资方 | 交易金额 | 融资轮次 | | --- | --- | --- | --- | | 2025-11-02 | 中美绿色基金 | 未披露 | A轮 | | 2024-04-22 | 临空集团 | 未披露 | 股权融资 | | 2023-12-11 | 宽带智汇母基金 | 未披露 | Pre-A轮 | | 2022-12-13 | 依依股份 中美绿色真金 | 1550万人民币 | 天使+ | | | 个人投资者 | | | | | 英诺天使基金 | | | | 2022-10-20 | 泰有其余 | 未披露 | 天使轮 | | | 水木清华校友墓金 | | | 证券之星消息，根据天眼查APP于11月2日公布的信息整理，北京荷牧生物科技有限公司A轮融资，融 ...

Core Viewpoint - The report indicates that Beijing Kanglwei Biological Technology Co., Ltd. has shown significant revenue growth while still facing losses, marking a transition in its financial performance and business strategy [1] Financial Performance - As of the end of September, the company achieved total revenue of approximately 1.2763 million, representing a year-on-year increase of 106.53% [1] - The company reported a net loss of about 229 million, although this reflects a year-on-year reduction of 16.6% [1] - The net profit growth of 16.6% for the current quarter marks the first time in three years that the company has shifted from negative to positive growth in this metric [1] Business Overview - Founded in 2008, the company focuses on innovative vaccine research and industrialization, positioning itself as a high-tech enterprise [1] - It is recognized as a leader in HPV vaccine research in China, boasting the most comprehensive HPV vaccine product portfolio globally, including three-valent, nine-valent, and fifteen-valent vaccines [1] - The company transitioned from biopharmaceutical research to commercialization, indicating a strategic shift in its business model [1] Market Position - The company successfully listed on the Beijing Stock Exchange on March 15, 2023, under the fourth set of unprofitable standards, making it one of the few companies to do so [1] - It is also the first company to apply for dual listing on both the Beijing and Hong Kong stock exchanges [1]

Core Viewpoint - 百克生物 is committed to innovation-driven development in the booming global biopharmaceutical industry, with a well-structured and diverse research pipeline that enhances its competitive edge [1][2]. R&D Strategy - The company has established a tiered R&D strategy focusing on "upgrading, filling gaps, and innovative breakthroughs," creating a product matrix that addresses health needs across all demographics [1][3]. - The R&D model includes a "production generation, R&D generation, and reserve generation" approach, ensuring a comprehensive layout from mature product production to cutting-edge technology reserves [2]. Key Products and Pipeline - Core products in the "production generation" include varicella vaccine, nasal spray influenza vaccine (both freeze-dried and liquid forms), and attenuated live vaccine for herpes zoster, which support the company's growth [2]. - "R&D generation" products, such as acellular DTP vaccine and adjuvanted influenza vaccines, are currently in clinical stages, while "reserve generation" products like HSV-2 mRNA vaccine and Alzheimer's therapeutic vaccine lay the foundation for long-term development [2]. Technological Platforms - The company has developed five core technology platforms: virus large-scale culture, formulation and adjuvant technology, genetic engineering, bacterial vaccine technology, and mRNA vaccine technology, supporting 13 vaccine projects and 3 monoclonal antibodies for infectious disease prevention [3]. - The company has achieved breakthroughs in mRNA vaccines and recombinant protein vaccines, with proprietary adjuvants already applied in various vaccine formulations [3]. Recent Achievements - In the first ten months of the year, the company received one production license for liquid nasal spray influenza vaccine and submitted five clinical trial applications for adjuvanted influenza vaccines, with four already approved [3][4]. - The company is developing a multi-component HSV-2 mRNA vaccine that enhances immune response and has initiated Phase I clinical trials, which could significantly enrich its product pipeline [4]. - The Alzheimer's therapeutic vaccine is in preclinical research, showing promising safety and immunogenicity, with potential applications for early treatment and prevention in at-risk populations [4].

Core Viewpoint - The announcement details a strategic cooperation agreement between Liaoning Chengda Biological Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences, focusing on the prevention of vector-borne infectious diseases and collaborative research projects [2][15]. Group 1: Agreement Overview - The strategic cooperation agreement is an intention-based collaboration aimed at addressing emerging infectious diseases, particularly vector-borne diseases [2][10]. - The agreement was signed on October 21, 2025, in Shenyang, Liaoning Province [5]. - The agreement does not require board or shareholder approval, as it is an intention-based agreement [7][8]. Group 2: Parties Involved - The Institute of Microbiology is a research institution with a registered capital of 63.23 million yuan, located in Beijing [4]. - There is no related party relationship between the Institute of Microbiology and Chengda Biological [4]. Group 3: Cooperation Details - The cooperation will focus on joint research projects, strategic consulting for disease prevention, and deep integration of industry and academia [10][11]. - A joint laboratory will be established to support the development of a key laboratory for synthetic immunology and vaccine manufacturing [11]. - Both parties will share knowledge and conduct training to enhance technological capabilities in the field of infectious disease prevention [11]. Group 4: Impact on Company - The collaboration is expected to integrate top resources from the Institute of Microbiology with the company's vaccine development platform, accelerating the research and development of vaccines and biopharmaceuticals [15]. - The partnership aligns with the company's long-term strategy to focus on vaccines and expand into the biopharmaceutical sector, laying a solid foundation for building a biopharmaceutical industry cluster [15]. - The agreement is not expected to have a direct impact on the company's performance in 2025, with specific effects dependent on future project developments [2][15].

Core Insights - Company signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases and vector-borne disease prevention [2][3] - The collaboration aims to leverage both parties' resources and expertise to enhance research and development in vaccine and biopharmaceuticals [3] Group 1: Strategic Collaboration - The agreement emphasizes joint applications for national and provincial research projects to secure government support and resources [2] - Both parties will establish a long-term partnership to share resources and amplify their efforts in infectious disease prevention [2][3] Group 2: Research and Development Focus - The collaboration will enhance the company's vaccine development platform by integrating top-tier resources from the Institute of Microbiology [3] - The partnership aims to accelerate the R&D process for vaccines and biopharmaceuticals targeting emerging infectious diseases [3] Group 3: Intellectual Property and Confidentiality - Each party retains ownership of their respective intellectual property, with jointly developed results being co-owned as per specific agreements [3] - Both parties will maintain confidentiality regarding project details and proprietary technologies throughout the collaboration [3] Group 4: Long-term Strategy - The strategic cooperation aligns with the company's long-term strategy to focus on vaccines while expanding into the biopharmaceutical sector [3] - The agreement is considered an intention for collaboration and is not expected to have a direct impact on the company's performance until specific projects are advanced [3]

Core Viewpoint - Chengda Bio (688739) has signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on the prevention of emerging infectious diseases, particularly vector-borne diseases, and aims to jointly apply for national and provincial research projects [1][2]. Group 1: Strategic Cooperation - The agreement emphasizes collaboration in the field of emerging infectious disease prevention, leveraging both parties' resources and expertise to enhance research and development efforts [1]. - Chengda Bio and the Institute of Microbiology will establish a long-term partnership to share resources and amplify their respective strengths in vaccine and biopharmaceutical development [1][2]. Group 2: Research and Development Focus - The collaboration will focus on joint research projects targeting vector-borne disease prevention, with plans to apply for government support and resources to foster innovation [1]. - The strategic partnership aims to accelerate the development of vaccines and biopharmaceuticals for emerging infectious diseases, enriching Chengda Bio's innovation pipeline [2]. Group 3: Intellectual Property and Confidentiality - Each party retains ownership of their respective intellectual property, with jointly developed project outcomes being co-owned as per specific agreements [2]. - Both parties will maintain confidentiality regarding project details and proprietary technologies throughout the collaboration [2].

Core Insights - The Chengdu-Chongqing economic circle is experiencing unprecedented development vitality, with the economic total increasing from 6.3 trillion to 8.7 trillion yuan over five years, showcasing its significant support for high-quality development in the western region and nationwide [1] Industry and Company Developments Biopharmaceutical Sector - Companies like Olin Bio are focusing on innovative vaccine development, achieving significant sales in their tetanus vaccine and leading global research in recombinant Staphylococcus aureus vaccines, demonstrating that high R&D investment is crucial for core competitiveness [2] - Yuandong Bio is transforming through a combination of imitation and innovation, progressing from high-end generics to innovative drug development, providing a model for small and medium-sized pharmaceutical companies [2] Traditional Industry Transformation - Chongqing Pharmaceutical Holdings exemplifies traditional enterprise transformation through identity, business, and digital changes, enhancing growth and efficiency [3] - Huaxi Securities is strategically integrating into the Chengdu-Chongqing economic circle, focusing on unique business offerings to leverage local policy benefits and industry characteristics [3] Advanced Technology Sector - Zhongzi Technology has evolved over 20 years, turning laboratory innovations into market-ready products, and has established a business matrix encompassing catalysts, new energy, and new materials [3] - Reascent Technology is developing core technologies in ultra-fine fiber materials, expanding applications in air purification and insulation [4] - Silica Treasure Technology has become a leader in organic silicon sealing materials, achieving a comprehensive product system and multi-field layout [4] Niche Market Leaders - Shanwaishan has achieved international advanced levels in blood purification equipment, expanding its market presence both domestically and internationally [5] - Zhongguang Lightning Protection has built a unique technological moat through a full-chain approach to lightning protection, supported by a legacy of technical expertise [6] Conclusion - Companies across various sectors in the Chengdu-Chongqing region are leveraging innovation and resilience to contribute significantly to the economic landscape, marking a vibrant chapter in the development of the dual-city economic circle [6]